Jazz Pharmaceuticals plc 8K

Jazz Pharmaceuticals plans a private offering of $1.0 billion (plus up to $150 million additional) exchangeable senior notes due 2032 and may concurrently repurchase up to $225 million of its ordinary shares using existing cash under its share repurchase program.

On August 26, 2026, Jazz Pharmaceuticals plc announced that its wholly owned subsidiary, Jazz Investments I Limited, intends to conduct a private offering of $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $150 million of notes, and that Jazz expects to use the net proceeds for general corporate purposes. The notes, fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals, will be exchangeable under certain conditions into cash and, at the issuer’s election, cash, ordinary shares, or a combination thereof for any amount above principal, with interest payable semiannually and terms such as interest rate and initial exchange rate to be set at pricing. Concurrently with the pricing of the notes, Jazz plans to repurchase up to $225 million of its ordinary shares from purchasers of the notes in privately negotiated transactions, funded with existing cash and conducted under its July 2024 share repurchase program, which will reduce the remaining authorization and may affect the trading price of its shares and the effective exchange price of the notes. The offering and potential share repurchases are subject to market conditions and other factors, and the securities have not been registered under the Securities Act or other applicable securities laws.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

8K

Source Type

fda

Accession

0001193125-26-377073

Alert Tier

7